11/21
08:38 am
itrm
Iterum Therapeutics Regains Full Nasdaq Compliance [Yahoo! Finance]
High
Report
Iterum Therapeutics Regains Full Nasdaq Compliance [Yahoo! Finance]
11/21
08:30 am
itrm
Iterum Therapeutics Regains Full Nasdaq Compliance
Medium
Report
Iterum Therapeutics Regains Full Nasdaq Compliance
11/14
07:09 am
itrm
Iterum Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Iterum Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/14
07:00 am
itrm
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
Medium
Report
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
11/11
08:00 am
itrm
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Low
Report
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
10/28
05:00 am
itrm
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
High
Report
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/25
11:12 am
itrm
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections [Yahoo! Finance]
High
Report
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections [Yahoo! Finance]
10/25
11:03 am
itrm
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
High
Report
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/10
08:30 am
itrm
Iterum Therapeutics to Present Data at IDWeek 2024
Low
Report
Iterum Therapeutics to Present Data at IDWeek 2024
10/9
05:00 pm
itrm
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
Medium
Report
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
9/24
11:19 am
itrm
Iterum's oral sulopenem acceptance hinges on antibiotic stewardship efforts [Yahoo! Finance]
Medium
Report
Iterum's oral sulopenem acceptance hinges on antibiotic stewardship efforts [Yahoo! Finance]
9/10
08:01 am
itrm
Iterum Therapeutics plc (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
High
Report
Iterum Therapeutics plc (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
9/10
07:00 am
itrm
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
High
Report
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
9/6
04:45 pm
itrm
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference [Yahoo! Finance]
Medium
Report
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference [Yahoo! Finance]
9/6
04:30 pm
itrm
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
Medium
Report
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference